Board Changes
31/05/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230531:nRSe1038Ba&default-theme=true
RNS Number : 1038B NetScientific PLC 31 May 2023
For release: 07.00, 31 May 2023
NetScientific plc
("NetScientific" or "NSCI" or the "Company" or the "Group")
Board Changes: Appointment of New Non-Executive Chair
London, UK - 31 May 2023: NetScientific plc (AIM: NSCI), the investment and
commercialisation group with an international portfolio of innovative life
science, sustainability and industrial technology companies, is pleased to
announce the strengthening of its Board with the appointment of Charles Spicer
as its new independent Non-Executive Chair. He will also chair the Nominations
Committee and serve as a member of the Audit Committee and the Remuneration
Committee.
Charles will join the Company as a Non-Executive Director with immediate
effect, and he will then assume the role of Non-Executive Chair following the
closing of the Company's 2023 Annual General Meeting ("AGM"), which is
anticipated to be on or around 29 June 2023. Interim Non-Executive Chair,
Jonathan Robinson will continue in his role until the AGM, to facilitate an
orderly handover. Following the AGM Jonathan will continue to serve on the
Board as a Non-Executive Director, Senior Independent Director and Chair of
both the Audit Committee and the Remuneration Committee.
Charles Alexander Evan Spicer (aged 58) is an experienced chair and director
specialising in the medtech and life sciences industries. He advises both
public and private companies. He currently chairs Creo Medical Group plc,
IXICO plc, and Korn Wall Limited (KwickScreen). Furthermore, he serves as the
Chair for the UK Department of Health's Product Development Awards Selection
Panel B for Invention for Innovation (i4i). Charles previously held
directorships at Aircraft Medical (acquired by Medtronic Inc. in 2015) and
Stanmore Implants (acquired by Stryker Inc. in 2016).
Charles was previously Chief Executive of MDY Healthcare plc, a strategic
healthcare investor and, prior to that, Head of Healthcare Corporate Finance
at both Numis Securities and Nomura International. Charles has a PhD in
History from London University and an MA in History from Cambridge University.
Dr Ilian Iliev, Chief Executive Officer of the Company, commented:
"We are delighted to welcome Charles to our Board and are very much looking
forward to working with him. He has extensive experience as a chair,
director, and adviser to AIM companies, and importantly combines this with a
deep knowledge of our core investment sectors and financial services. These
attributes will prove highly valuable as we continue to execute on our growth
strategy.
"I would also like to acknowledge the contributions of Jonathan Robinson, who
served as interim Chair. We are extremely grateful to him for his interim
board leadership, supporting the final stages of our turnaround project. His
measured and practical approach contributed greatly to its success and we look
forward to our continued work together."
Charles currently holds or has held in the past five years the following
directorships and partnerships:
Current directorships and partnerships Past directorships and partnerships
Creo Medical Group plc 11 Health & Technologies Ltd
IXICO plc MJ Hudson Group plc
Korn Wall Ltd Realm Therapeutics Ltd
Newe House Partners
Charles Spicer does not hold any interest in the share capital of the Company.
No further disclosure is required under paragraph (g) of Schedule Two of the
AIM Rules for Companies.
-Ends-
The person responsible for arranging the release of this announcement on
behalf of the Company is Ilian Iliev, Chief Executive Officer of the Company.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY
VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
For more information, please contact:
NetScientific
Ilian Iliev,
CEO
Via Belvedere Communications
WH Ireland (Nominated adviser and broker)
Chris Fielding / Darshan Patel / Enzo
Aliaj
+44 (0)20 7220 1666
Belvedere Communications
John West / Llew
Angus
+44 (0) 203 008 6867
Email: nsci@belvederepr.com (mailto:nsci@belvederepr.com)
About NetScientific
NetScientific plc (AIM: NSCI) is an investment and commercialisation group
with an international portfolio of innovative life science, sustainability and
technology companies.
NetScientific identifies, invests in, and builds high growth companies in the
UK and internationally. The company adds value through the proactive
management of its portfolio, progressing to key value inflection points, and
delivering investment returns through partial or full liquidity events.
NetScientific differentiates itself by employing a capital-light investment
approach, making judicial use of its balance sheet and syndicating investments
through its wholly owned VC subsidiary, EMV Capital. The group secures a
mixture of direct equity stakes and carried interest stakes in its portfolio
of companies, creating a lean structure that can support a large portfolio.
NetScientific is headquartered in London, United Kingdom, and is admitted to
trading on AIM, a market operated by the London Stock Exchange.
www.netscientific.net (http://www.netscientific.net/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BOAABMMTMTJJMPJ